Clinical Trial

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
Trial Details
NCT Number NCT07511062
Lead Sponsor Northside Hospital, Inc.
Collaborators: Incyte Corporation
Conditions Acute Myeloid Leukemia, TP53 Gene Mutation
Enrollment 32 participants
Start Date 2026-08-01
Primary Completion 2029-08-01 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-06